Feb 7 (Reuters) – Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Pune (Maharashtra) [India], May 9: In 2026, skincare has evolved beyond surface-level treatments into a…
This alliance brings enterprise consulting and AI-enabled engagement capabilities together for customer-centric transformation. Mumbai (Maharashtra)…
Neat Singapore, May 8: Neat, the pioneering video technology company, today announced the appointment of…
New Delhi [India], May 8: Steris Healthcare Pvt Ltd is bolstering its digital marketing and…
Pune (Maharashtra) [India], May 8: Marking National Technology Day, QAD | Redzone will inaugurate its…
Jaipur (Rajasthan) [India], May 7: In recent years, the way businesses communicate with their audience…